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Summary
 
Neurofibromin, the protein encoded by the 
 
NF1
 
 tumor-suppressor gene, negatively regulates
the output of p21
 
ras 
 
(Ras) proteins by accelerating the hydrolysis of active Ras-guanosine triphos-
phate to inactive Ras-guanosine diphosphate. Children with neurofibromatosis type 1 (NF1)
are predisposed to juvenile chronic myelogenous leukemia (JCML) and other malignant my-
eloid disorders, and heterozygous 
 
Nf1
 
 knockout mice spontaneously develop a myeloid disorder
that resembles JCML. Both human and murine leukemias show loss of the normal allele. JCML
cells and
 
 Nf1
 
2/2
 
 hematopoietic cells isolated from fetal livers selectively form abnormally high
numbers of colonies derived from granulocyte-macrophage progenitors in cultures supple-
mented with low concentrations of granulocyte-macrophage colony stimulating factor (GM-
CSF). Taken together, these data suggest that neurofibromin is required to downregulate Ras
activation in myeloid cells exposed to GM-CSF. We have investigated the growth and prolif-
eration of purified populations of hematopoietic progenitor cells isolated from 
 
Nf1
 
 knockout
mice in response to the cytokines interleukin (IL)-3 and stem cell factor (SCF), as well as to
GM-CSF. We found abnormal proliferation of both immature and lineage-restricted progeni-
tor populations, and we observed increased synergy between SCF and either IL-3 or GM-CSF
in 
 
Nf1
 
2/2
 
 progenitors. 
 
Nf1
 
2/2
 
 fetal livers also showed an absolute increase in the numbers of
immature progenitors. We further demonstrate constitutive activation of the Ras-Raf-MAP
(mitogen-activated protein) kinase signaling pathway in primary c-kit
 
1
 
 
 
Nf1
 
2/2
 
 progenitors and
hyperactivation of MAP kinase after growth factor stimulation. The results of these experi-
ments in primary hematopoietic cells implicate 
 
Nf1
 
 as playing a central role in regulating the
proliferation and survival of primitive and lineage-restricted myeloid progenitors in response to
multiple cytokines by modulating Ras output.
Key words: neuroﬁbromin • hematopoietic progenitor • cytokines • Ras • granulocyte/
macrophage colony–stimulating factor
 
R
 
as proteins regulate the growth and differentiation of
many cell types by acting as molecular switches that
transduce signals from the extracellular environment to the
nucleus (1–9). The biochemical output of Ras proteins is
tightly regulated by their ability to cycle between an active
guanosine triphosphate (GTP)-bound state (Ras-GTP) and
an inactive guanosine diphosphate (GDP)-bound state
(Ras-GDP) (1–4). Ras activation is an essential component
of proliferative responses induced after receptor binding by
a variety of growth factors including IL-3, GM-CSF, CSF-1,
and stem cell factor (SCF)
 
1
 
 (5–9). Stimulation by each of
these cytokines induces an increase in the percentage of
Ras-GTP in the target cell (5, 6, 8, 9). Ras-GTP recruits
Raf-1 to the plasma membrane and Raf-1, in turn, acti-
 
1
 
Abbreviations used in this paper:
 
 CFC, colony-forming cells; GAP, GTPase-
activating protein; HPP, high proliferating potential; JCML, juvenile
chronic myelogenous leukemia; LPP, low proliferating potential; MAP,
mitogen-activated protein; MBP, myelin basic protein; MEK, MAP ki-
nase/extracellular signal-regulated kinase; NF1, neurofibromatosis type 1;
SCF, stem cell factor.
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vates a series of downstream effectors such as mitogen-acti-
vated protein (MAP) kinase (7, 10, 11). GTPase-activating
proteins (GAPs) regulate Ras output by stimulating the
slow intrinsic Ras GTPase (4, 12, 13). Because it is Ras-
GTP that transduces signals, GAPs act (at least in part) as
negative regulators of Ras function (1–4, 12). Two GAPs,
p120 GAP (also known as Ras-GAP) and neurofibromin
(the protein encoded by the 
 
NF1
 
 gene) regulate Ras out-
put in mammalian cells (4, 12–15) by promoting the con-
version of Ras-GTP to Ras-GDP (4).
Mutations of 
 
NF1
 
 cause neurofibromatosis type 1 (NF1),
an autosomal dominant disorder with an incidence of 1 in
4,000 (14–18). Affected individuals are predisposed to the
development of benign and malignant neoplasms that arise
primarily in cells derived from the embryonic neural crest
(14–19). In addition, children (but not adults) with NF1
have a markedly increased risk of developing malignant
myeloid disorders and comprise as many as 10% of de novo
cases of preleukemia in the pediatric age group (19–24). Ju-
venile chronic myelogenous leukemia (JCML), a myeloprolif-
erative syndrome characterized by leukocytosis, thrombocy-
topenia, and hepatosplenomegaly with infiltrates of myeloid
cells, is the most common leukemia seen in children with
NF1 (20–25). Genetic and biochemical data from studies of
human leukemias have shown that 
 
NF1
 
 functions as a tu-
mor suppressor gene in hematopoietic cells by negatively
regulating Ras signaling (20, 22–25). Mice that are het-
erozygous for a targeted disruption of 
 
Nf1 
 
are predisposed
to a number of cancers including myeloid leukemia (26).
Leukemic cells from these animals show loss of the normal
 
Nf1
 
 allele (26). Although mice homozygous for disruption
of 
 
Nf1
 
 die during embryonic development, 
 
Nf1
 
2/2
 
 fetal
liver cells efficiently reconstitute hematopoiesis and consis-
tently induce a JCML-like myeloproliferative syndrome in
irradiated recipients (27).
A hallmark of low density blood and bone marrow cells
from children with JCML is an abnormal pattern of in vitro
progenitor growth that is characterized by the appearance
of factor-independent myeloid colonies in methylcellulose
cultures (28, 29). A second consistent finding is that JCML
cells form higher numbers of colonies derived from lin-
eage-restricted colony-forming unit granulocyte-macrophage
progenitors (CFU-GM) in the presence of low concentra-
tions of GM-CSF (21, 28, 29). Hypersensitive growth has
not been observed in cultures in which IL-3 or GM-CSF was
added, and these results have led to the hypothesis that a
specific defect within the GM-CSF signal transduction
pathway plays a central role in the pathogenesis of JCML
(28, 29). 
 
Nf1
 
2
 
/
 
2
 
 fetal liver cells also demonstrate a similar
pattern of selective GM-CSF hypersensitivity in myeloid
progenitor assays (27, 30) and provide a model system to
investigate both the role of neurofibromin in regulating
Ras signaling in hematopoietic cells and also the pathogen-
esis of JCML.
We have used 
 
Nf1
 
 mice to address two questions related
to the role of neurofibromin in regulating hematopoietic
cell growth through the Ras-MAP kinase pathway. First,
since the hematopoietic system is hierarchial and has multi-
ple compartments, it is possible that neurofibromin is only
required to regulate growth of specific subpopulations of
cells in response to a restricted number of hematopoietic
growth factors. Previous studies of human and murine cells
examined only the responsiveness of relatively differenti-
ated, lineage-restricted progenitors from mixed populations
of hematopoietic cells, and in most instances cultures were
established using single growth factors (21, 27, 29–33). We
isolated highly pure hematopoietic progenitors and exam-
ined their growth in response to GM-CSF, IL-3, and stem
cell factor (SCF) singly and in combination with other fac-
tors. SCF promotes the survival and proliferation of imma-
ture, multilineage hematopoietic progenitors (34–37) and
acts synergistically with growth factors, such as GM-CSF,
that primarily affect differentiated, lineage-restricted cells
(38–41). Second, the selective hypersensitivity of 
 
Nf1
 
2/2
 
and JCML cells to GM-CSF in colony-forming assays is
perplexing because GM-CSF and IL-3 both increase Ras-
GTP levels in cell lines (8, 9) and the cell surface receptors
for these ligands share a common 
 
b
 
 chain that transduces
signals (for review see references 42–44). To address these
questions, we measured constitutive and cytokine-stimu-
lated MAP kinase activation in well-defined populations of
primary 
 
Nf1
 
2/2
 
 and 
 
Nf1
 
1/1
 
 hematopoietic cells and corre-
lated these data with in vitro colony-forming assays that as-
sessed the size and growth factor responsiveness of these
populations. Our results implicate neurofibromin as regu-
lating the size and growth factor responsiveness of both
immature and lineage-restricted hematopoietic progenitor
populations by modulating Ras output in response to mul-
tiple cytokines. 
 
Materials and Methods
 
Isolation of Fetal Hematopoietic Cells.
 
Heterozygous 
 
Nf1
 
1/2
 
 
 
mice
were mated to produce 
 
Nf1
 
2/2
 
 
 
embryos. Pregnant 
 
Nf1
 
1/2
 
 fe-
males were killed by cervical dislocation on day 13.5 of gestation
and the embryos were removed through an anterior abdominal
incision. After individual embryos were isolated, each fetal liver
was removed and transferred to a 10 
 
3 
 
35 mm dish in IMDM
supplemented with 20% FCS. A single cell suspension was pre-
pared by pushing the hepatic tissues through progressively smaller
needles (16–27 gauge). This procedure yielded 1–1.5 
 
3 
 
10
 
7
 
mononuclear cells.
 
Genotyping Fetal Tissues.
 
Once the liver was removed, the re-
mainder of the embryonic tissues were used for genotype analysis.
Genomic DNA from fetal tissues were isolated as previously de-
scribed (30). An assay based on the PCR was used to perform
genotype analysis. The targeting vector used to disrupt the mu-
rine 
 
Nf1
 
 gene truncates exon 31 and inserts a neomycin resistance
gene (
 
neo
 
). The 3
 
9
 
 (reverse) primer is complimentary to a se-
quence in the 3
 
9
 
 region of exon 31 that is present in both wild-
type and targeted 
 
Nf1
 
 genes. Two 5
 
9
 
 primers were designed to
distinguish disrupted and wild-type genes. The first is compli-
mentary to 
 
neo
 
 and the second is complimentary to a wild-type
exon 31 sequence. Amplification with the 
 
neo
 
 and 3
 
9
 
 
 
Nf1
 
 primer
pair yields a 350-bp product, whereas amplification with the 5
 
9
 
Nf1
 
 and 3
 
9
 
 
 
Nf1 
 
pair gives a 230-bp fragment. The sequences for 
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the PCR primers used in these studies are: 5
 
9
 
 
 
Nf1
 
 exon 31:
CACCTTTGTTTGGAATAT, 3
 
9
 
 
 
Nf1
 
 exon 31: TTCAATAC-
CTGCCCAAGG, and 
 
neo
 
: ATTCGCCAATGACAAGAC.
 
Transplantation into Irradiation-conditioned Congenic Mice.
 
Unfrac-
tionated fetal liver cells (1–2 
 
3 
 
10
 
6
 
) from 
 
Nf1
 
2
 
/
 
2
 
 or 
 
Nf1
 
1/1
 
 litter-
mates were transplanted into C57Bl/6J recipient mice condi-
tioned with 1,100 rads of gamma irradiation from a Cs source
(Gamma cell 40 Extractor; MDS Nordion Kanata, Ontario, Can-
ada) with 700 rads given in the first dose and 400 rads given 4 h
later. Recipients of 
 
Nf1
 
2
 
/
 
2
 
 cells consistently develop myeloprolif-
erative hematopoiesis with large numbers of mature neutrophils
and monocytes in the peripheral blood and prominent splenomeg-
aly (27). Bone marrow and splenic cells were obtained from re-
cipients 18–30 wk after transplantation. Hematopoietic cells were
evaluated at death by PCR to confirm the detection of only do-
nor-derived cells.
 
Purification of Hematopoietic Progenitors.
 
Low density cells were
incubated with a PE-conjugated c-kit monoclonal antibody or a
PE-conjugated Sca1
 
1
 
 monoclonal antibody whose corresponding
Ly6A/E antigen is highly expressed on all primitive hematopoi-
etic progenitors and cells in the stem cell compartment in C57Bl6
strain (45). Cells were incubated with 1 
 
m
 
g of c-kit or Sca1 anti-
body/10
 
6
 
 cells, (PharMingen, San Diego, CA), and the cells were
then incubated on ice for 20 min, pelleted, washed, repelleted,
and then suspended in FACS buffer. Cells were also simultaneously
stained with antibodies to the following lineage markers includ-
ing: anti-B220, anti-CD3
 
e
 
, anti–Gr-1, and anti–Mac 1 all conju-
gated to FITC (PharMingen). They were then separated by
FACS
 
Ò
 
 using a dual laser FACStar PLUS
 
Ò
 
 equipped with an argon
and a krypton laser (Becton Dickinson, Mountain View, CA).
 
Hematopoietic Progenitor Colony Growth.
 
Recombinant GM-CSF,
IL-3, and SCF were obtained from Peprotech (Rocky Hill, NJ);
recombinant mIL-1
 
a
 
 and M-CSF were purchased from R&D
Research Laboratories (Minneapolis, MN). Purified hematopoi-
etic cells were placed into culture in triplicate 35-mm plates at a
final concentration of 5 
 
3 
 
10
 
2
 
 cells per ml. Cells and recombinant
growth factors were added to the methylcellulose medium, (for
growth of CFU-GM) or agar (for growth of low proliferating po-
tential [LPP] colony-forming cells [CFC] and high proliferating
potential [HPP]-CFC) and the solution was thoroughly admixed
before plating as previously described (30, 46, 47). Cells cultured
for growth of CFU-GM were maintained at 37
 
8
 
C in a humidi-
fied 5% CO
 
2
 
 incubator 95% O
 
2
 
 and scored on day 10 of culture.
Growth factors used for culture of HPP-CFC and LPP-CFC in-
cluded SCF, IL-1
 
a
 
, CSF-1, and GM-CSF or IL-3. Cultures for
growth of LPP-CFC were cultured in 8% CO
 
2
 
, 5% O
 
2
 
, and were
scored on day 7 of culture, whereas those for HPP-CFC were scored
on day 14 of culture. Colonies were scored by indirect microscopy.
 
Kinase Assays.
 
The incorporation of phosphate into myelin
basic protein (MBP) (Sigma Chemical Co., St. Louis MO) was
used as a measure of MAP kinase activity as previously described
(48–51). Cell pellets were lysed in lysis buffer (10 mM K
 
2
 
HPO
 
4
 
,
1 mM EDTA, 5 mM EGTA, 10 mM MgCl
 
2
 
, 1 mM Na
 
3
 
 V0
 
4
 
, 50
mM 
 
b
 
-glycerophosphate, 1% NP-40, 10 
 
m
 
g/ml leupeptin, 1 mg/ml
pepstatin, and 100 mg/ml PMSF) at 48C, disrupted in 1 ml of
Dounce (Kontes, Vineland, NJ), iced for 30 min, and clarified by
ultracentrifugation at 100,000 g for 30 min at 48C. Total protein
was determined using a BCA protein assay kit (Pierce, Rockford,
IL). The MBP reaction conditions consisted of 10 ml of cell lysate
with 5 mg of MBP substrate and was incubated with 20 mM Tris-
Hcl pH 7.25, 10 mM MgCl2, 500 mM unlabeled ATP, 20 mg
BSA, and 5 mCi g-[32P]ATP in a total reaction volume of 30 ml,
at 308C 3 159. Three replicates of each reaction were evaluated
in each experiment. The reactions were stopped by the addition
of 7.5 ml of 53 sample buffer and were then boiled for 2 min.
The kinase reaction mixtures were resolved on 12.5% SDS-
PAGE gels. Gels were then stained in a 0.2% Coomassie brilliant
blue (Boehringer Mannheim, Indianapolis, IN) solution, dried on
Whatman paper, and exposed to Kodak x-OMAT AR film (East-
man-Kodak Co., Rochester, NY) at 2208C. In addition to auto-
radiography, radiolabeled phosphate in MBP gel bands was also
determined by liquid scintillation counting of the MBP bands.
The cpm value was then used to calculate MAP kinase activity in
pmol phosphate incorporated into MBP/min/mg protein in the
cell lysate.
Liquid Cultures. Purified populations of c-kit1 cells isolated
from the bone marrows of mice transplanted with Nf12/2 or
Nf11/1 cells were treated with the MAP kinase/ERK (extracellu-
lar signal–regulated) kinase (MEK) inhibitor PD 98059 (New En-
gland Biolabs, Beverly, MA) to a final concentration of 50 mM as
previously described (52). All cultures were maintained at a den-
sity of 2 3 105 cells/ml in IMDM supplemented with 20% FCS.
Cells were cultured in 100 ng/ml rmSCF and 50 U/ml rmIL-3,
which is the maximum stimulating activity of each respective cy-
tokine.
Results
Previous studies in JCML bone marrow samples have
implicated cytokine production by accessory cells as con-
tributing to the hypersensitive pattern of myeloid progeni-
tor growth (31, 32). We therefore isolated highly pure (95–
99%) Sca11lin2/dim cells derived from day 13.5 fetal livers
by flow cytometric cell sorting and assayed the growth of
CFU-GM in methylcellulose medium supplemented with
varying concentrations of either GM-CSF or IL-3. A rep-
resentative FACSÒ analysis of cells before and after cell
sorting is shown in Fig. 1. The results of four independent
experiments indicate that CFU-GM derived from Nf12/2
fetal liver Sca11lin2/dim cells retain a hypersensitive pattern
of colony formation in response to GM-CSF but not IL-3
Figure 1. Isolation of Sca11lin2/dim hematopoietic progenitors from fe-
tal liver cells. Pooled day 13.5 gestation fetal liver cells from each respec-
tive genotype were prepared for culture by isolation of low density cells
using a Ficoll-Hypaque gradient. Low density cells were simultaneously
stained with isotype controls or antibodies to Sca1 (PE) and lineage mark-
ers including anti-B220 (pan–B lymphocytes), anti-CD3e (pan–T cells),
anti–Gr-1 (granulocytes), and anti–Mac 1 (monocyte-macrophages) all con-
jugated to FITC. Sca11lin2/dim cells were identified relative to isotype con-
trol antibodies in the upper left corner of the dual parameter dot plot in A.
These cells were isolated by fluorescence-activated cell sorting and a sam-
ple of sorted cells was reanalyzed to confirm the purity of isolated cells (B).1896 Nf1 Regulates Hematopoietic Progenitor Cell Growth
(Fig. 2, a and b). These data suggest that the alteration of
growth responsiveness to GM-CSF seen in Nf12/2 cells is
intrinsic to the progenitor compartment.
We next examined the effects of adding a low concen-
tration of murine SCF (10 ng/ml) in combination with ei-
ther GM-CSF or IL-3 on Sca11lin2/dim cells on colony for-
mation. CFU-GM colony growth under these conditions
is shown in Fig. 2, c and d, and the absolute numbers of
progenitor colonies enumerated at maximal concentrations
of GM-CSF or IL-3 singly and in combination with SCF
are shown in Table 1. As with GM-CSF alone, the dose–
response curve for CFU-GM colony formation from Nf12/2
cells was significantly left-shifted relative to Nf11/1 cells in
cultures stimulated with GM-CSF 1 SCF (Fig. 2 c). The
hypersensitive pattern of growth seen in Nf12/2 cells was
more pronounced in parallel cultures stimulated with GM-
CSF and SCF than in plates containing GM-CSF alone,
and there was an increase in the absolute number of pro-
genitors enumerated (Table 1). Surprisingly, the addition of
SCF to cultures stimulated with IL-3 induced a hypersensi-
tive pattern of growth in Nf12/2 cells (Fig. 2 d) that was not
seen with IL-3 alone (Fig. 2 b). Although SCF is relatively
inefficient at inducing colony formation in the absence of
other growth factors (Table 1), we also detected a signifi-
cant left shift in the dose–response curve of Nf12/2 versus
Nf11/1 cells cultured in the presence of SCF alone (Fig. 2 e).
Taken together, these data suggest that loss of Nf1 deregu-
lates the growth of hematopoietic progenitors in response
to SCF, which acts on more immature populations of pro-
genitors than do IL-3 or GM-CSF, and demonstrate that
SCF can synergize with either factor to induce a hypersen-
sitive pattern of in vitro growth in Nf12/2 progenitors.
One potential explanation for the hypersensitive growth
seen in response to SCF alone or in combination with IL-3
is that SCF stimulation induces autocrine production of
GM-CSF by Nf12/2 progenitor cells. To test this hypothe-
sis, an anti–GM-CSF neutralizing antibody was added to
the methylcellulose cultures stimulated with a combination
of IL-3 and SCF. In pilot experiments, a concentration of
anti–GM-CSF antibody that completely blocked CFU-GM
colony formation in response to 10 U/ml of GM-CSF
(maximum stimulating activity) was established and used
Figure 2. Dose–response curves
of progenitor colony growth in
response to cytokines. Growth of
Sca11lin2/dim  cells from wild-
type (Nf11/1), heterozygous
(Nf11/2), and homozygous
(Nf12/2) mice is shown at the in-
dicated concentrations of mGM-
CSF (a), mIL-3 (b), mGM-CSF
and 10 ng/ml SCF (c), mIL-3
and 10 ng/ml mSCF (d), or
mSCF (e). The data are ex-
pressed as percentage of maximal
numbers of CFU-GM colonies.
Table 1. Maximal CFU-GM/5 3 102 Sca11/lin2/dim in 
Response to Cytokine Stimulation
Cytokine
Genotype
2/21 / 21 / 1
GM-CSF (10 ng/ml) 71 6 8.5 70 6 11.2 68 6 7.5
IL-3 (50 U/ml) 73 6 15.6 68 6 14.4 80 6 14.3
GM-CSF (10 ng/ml) 1
SCF (10 ng/ml) 119 6 23.0 89 6 15.6 96 6 12.3
IL-3 (50 U/ml) 1
SCF (10 ng/ml) 117 6 20.8 110 6 12.7 105 6 15.6
SCF (100 ng/ml) 57 6 16.1 47 6 6.5 46 6 8.3
The colonies enumerated from each respective genotype after stimula-
tion with cytokines that yielded maximum colony activity. (See Fig. 2).
Results are expressed as mean 6 SE. All data represent analysis from
four independent experiments.1897 Zhang et al.
in subsequent experiments (data not shown). Fig. 3 sum-
marizes the results of three independent experiments exam-
ining the number of CFU-GM colonies seen when either
anti–GM-CSF or an isotype control antibody was added
to cultures containing IL-3 1 SCF. These data indicate
that the abnormal pattern of CFU-GM colony formation
observed in Nf12/2 Sca11lin2/dim cells is maintained in the
presence of anti–GM-CSF antibody, and therefore we con-
clude that hypersensitive growth in the presence of IL-3 1
SCF is not due to autocrine GM-CSF production by Nf12/2
cells.
The experiments described above assayed the growth of
colonies derived from CFU-GM, a relatively differentiated,
lineage-restricted population of myeloid progenitors. How-
ever, data from cultures stimulated with SCF suggested
that neurofibromin might also regulate the growth of more
primitive hematopoietic compartments. To investigate this
possibility, two-layer agar cultures were established to assay
the growth of primitive progenitors with significant re-
plating potential indicative of a primitive stem/progenitor
cell (46) and referred to as HPP-CFC. Fetal liver cells from
Nf12/2, Nf11/2, and Nf11/1 embryos were cultured in two
different combinations of four growth factors at saturat-
ing activities to enumerate HPP-CFC. The frequency of
HPP-CFC observed in cultures were then multiplied by
the number of low density cells per organ to calculate the
absolute number of HPP-CFC per fetal liver. The results
shown in Fig. 4 demonstrate that significantly higher numbers
of HPP-CFC are present from the Nf12/2 fetal liver cells.
The data suggest that the loss of Nf1 results in an expansion
of HPP-CFC in vivo in the fetal liver and that neurofibro-
min is important in modulating the growth of primitive
myeloid progenitor compartments as well as CFU-GM
progenitors.
Stimulation with a variety of growth factors including
SCF, GM-CSF, or IL-3 activates the Ras-Raf-MAP kinase
cascade in cultured cell lines (5–9). We hypothesized that if
neurofibromin is critical to regulate Ras signaling in re-
sponse to these cytokines in primary hematopoietic pro-
genitors, then loss of Nf1 function might result in an aug-
mented MAP kinase activity after stimulation. To test this
possibility, c-kit1 cells were isolated from the bone mar-
rows of mice previously irradiated and then reconstituted
with fetal liver cells from day 13.5 gestation Nf12/2 and
Nf11/1 littermates. In pilot experiments, we determined
that the c-kit1 cells isolated from transplant recipients had a
similar hyperresponsiveness to GM-CSF in clonogenic as-
says as did Nf12/2 fetal liver cells (data not shown). After
isolation using fluorescence-activated cell sorting, c-kit1
cells were maintained in liquid cultures overnight without
exogenous growth factors. The cells were then stimulated
with either SCF, IL-3, or GM-CSF alone or with a combi-
nation of SCF 1 IL-3. MAP kinase activity was measured
in unstimulated cells as well as at 5 and 60 min after the ad-
dition of growth factor(s). Three independent experiments
yielded similar results; data from one of these is shown in
Fig. 5. A threefold elevation in MAP kinase activity was
Figure 3. Progenitor colony
growth in response to varying
concentrations of IL-3 and SCF
in the presence of neutralizing
anti–GM-CSF antibodies. Growth
of Sca11lin2/dim from wild-type
(Nf11/1) and homozygous (Nf12/2)
mice is shown at the indicated
concentrations of mIL-3 and 10
ng SCF in the presence of anti–
GM-CSF neutralizing antibod-
ies or isotype control antibodies.
Figure 4. Growth of colonies
derived from primitive progeni-
tors in fetal livers. Total numbers
of HPP-CFC from wild-type
(Nf11/1), heterozygous (Nf11/2),
and homozygous (Nf12/2) fetal
livers are shown after culture in
saturating concentrations of SCF,
M-CSF, IL-1a, and either GM-
CSF (A) or IL-3 (B).
Figure 5. MAP kinase activity in c-kit1 hematopoietic cells. c-kit1
bone marrow cells from mice previously reconstituted with Nf12/2 or
Nf11/1 fetal liver cells were isolated, stimulated with cytokines for speci-
fied times, and harvested, and cell lysates were prepared. MAP kinase ac-
tivity was measured in whole cell extracts. Activity was calculated by de-
termining the rate of incorporation of phosphate in MBP per min/mg of
lysate and is indicated in the graph for each genotype, cytokine, and
length of stimulation. The genotype and length of stimulation are indi-
cated.1898 Nf1 Regulates Hematopoietic Progenitor Cell Growth
observed in unstimulated c-kit1 cells isolated from the
Nf12/2  recipients. Kinase activity increased significantly in
Nf12/2 cells after exposure to IL-3, SCF, or SCF 1 IL-3,
and persisted above baseline at 60 min. There was also an
increase in MAP kinase activity at 60 min after stimulation
with GM-CSF that approached statistical significance. In
contrast, c-kit1 cells from the Nf11/1 recipients had a much
less pronounced increase in MAP kinase activity at 5 min
after stimulation, and the kinase returned to baseline by 60
min. We conclude that absence of neurofibromin in c-kit1
hematopoietic progenitors results in a constitutive activa-
tion of Ras-MAP kinase signaling that can be further stim-
ulated in response to SCF, IL-3, and GM-CSF.
To confirm an association between the clonogenic and
biochemical data presented above, c-kit1 cells were again
isolated from transplant recipients. MAP kinase activity was
determined on aliquots of Nf11/1 and Nf12/2 cells after
overnight incubation in the presence or absence of an in-
hibitor of MEK. The remaining cells were either immedi-
ately cultured in methylcellulose to score the growth of
myeloid progenitor colonies or were placed into liquid cul-
ture containing SCF and IL-3 together with MEK or the
vehicle control for 48 h before plating. Biochemical data
from one of three representative experiments are shown in
Fig. 6 and the colony numbers are presented in Fig. 7. Ad-
dition of the MEK inhibitor reduced the MAP kinase ac-
tivity of unstimulated Nf12/2 cells to wild-type levels and
blocked kinase activation in response to SCF and IL-3.
Similarly, addition of the MEK inhibitor to liquid cultures
of c-kit1 cells for 48 h before plating in methylcellulose
markedly decreased the growth of differentiated cells, dif-
ferentiated progenitor cells (LPP-CFC), and primitive he-
matopoietic progenitors (HPP-CFC) as compared with
cultures containing the vehicle only. A reduced biochemi-
cal and cellular response to the MEK inhibitor was noted in
the Nf11/1 hematopoietic cells. Taken together, these data
implicate deregulated signaling through the Ras-MEK-
MAP kinase in the aberrant pattern of cytokine-induced
hematopoietic progenitor colony growth seen in Nf12/2
cells.
Discussion
Ras signaling plays a central role in normal myelopoiesis
and is deregulated by at least three distinct genetic mecha-
nisms in myeloid leukemia (for review see references 20,
53, 54). Ligand-induced activation of many hematopoietic
growth factor receptors transiently increases the Ras-GTP
levels, which in turn influences the survival, proliferation,
and differentiation of myeloid-lineage cells. In leukemic
cells, acquired mutations of NRAS or KRAS, formation of
a chimeric protein as a result of BCR-ABL translocations,
and inactivation of NF1 all deregulate Ras signaling. Lines
of knockout mice provide novel model systems for ascer-
taining how loss of function of specific genes influences
complex biologic processes such as hematopoiesis and leu-
kemogenesis. Although inactivation of the murine homo-
logues of many human tumor suppressor genes results in a
spectrum of neoplasms that differs significantly from the re-
spective human cancers, Nf1 mice spontaneously develop a
type of leukemia that closely resembles JCML and Nf12/2
cells display a similar pattern of GM-CSF hypersensitivity
in myeloid colony-forming assays.
A distinct advantage of this murine model is the ability
Figure 6. Inhibition of MAP kinase activity in Nf12/2 c-kit1 cells ex-
posed to MEK inhibitor before stimulation with cytokines. c-kit1 bone
marrow cells from mice reconstituted with Nf12/2 fetal liver cells (left) or
Nf11/1 (right) were exposed to a MEK inhibitor or vehicle control before
stimulation with a maximum stimulating capacity of IL-3 and SCF. Cells
were lysed 5 min after stimulation with cytokines. The autoradiographs
and activities of one of three independent experiments is shown. The cy-
tokine and MEK inhibitor treatment of cells is indicated by 1 or 2.
Figure 7. Effect of preincubation with an MEK inhibitor on progeni-
tor colony formation from Nf12/2 cells. c-kit1 bone marrow cells (4 3
104) were cultured with SCF and IL-3 for 48 h in the presence of the
MEK inhibitor (MEKI) or the vehicle control (DMSO). After liquid cul-
ture, progenitor assays for growth of HPP-CFC and LPP-CFC were es-
tablished. The total number of nucleated cells (A), LPP-CFC (B), and
HPP-CFC (C) after culture for each genotype and condition are indi-
cated. Based on cultures established in agar before treatment with the
MEK inhibitor, 1,850 LPP-CFCs 6 10 SEM and 260 HPP-CFC 6 40
SEM per well were present in the input Nf12/2 cells, and 825 LPP-CFC 6
205 SEM and 100 HPP-CFC 6 40 SEM were present in input Nf11/1 cells.1899 Zhang et al.
to reconstitute irradiated mice only lacking Nf1 and isolate
highly purified populations of phenotypically defined cells
to characterize their in vitro colony growth and intracellu-
lar signaling.
This study addressed two questions: (a) what is the role
of neurofibromin in modulating the cytokine responsive-
ness and growth of both primitive myeloid progenitors
with multilineage and replating potential, and of more dif-
ferentiated lineage-restricted myeloid progenitors?, and (b)
how does inactivation of Nf1 affect constitutive and cyto-
kine-stimulated intracellular signaling through the Ras-Raf-
MAP kinase pathway in these primary hematopoietic cells?
We used antibodies to purify immature hematopoietic cells
and focused on the SCF/c-kit signaling pathway because
the binding of SCF to c-kit increases Ras-GTP levels and
activates Raf-1 and MAP kinase activity in myeloid cell
lines (7). In addition, the presence of multiple hematopoie-
tic defects in lines of mice with mutations affecting either
c-kit (dominant white spotting, W) or SCF (Steel) (34–37,
39, 55, 56), as well as numerous in vitro studies showing a
synergistic effect between SCF and other cytokines in pro-
moting the survival and proliferation of primitive hemato-
poietic progenitor cells, indicate that the SCF/c-kit signal-
ing plays an important role in early hematopoiesis (38–41).
An intriguing finding demonstrated here was that SCF
alone or in combination with IL-3 induced a hypersensi-
tive pattern of CFU-GM colony growth in Nf12/2 cells.
Though some reports using JCML cells have observed hy-
persensitive colony growth in response to only GM-CSF,
others have inferred the involvement of other cytokines in
the pathogenesis of the myeloproliferative disease (31–34,
57). Our results address an interesting paradox: since the
GM-CSF and IL-3 receptors share a common b signaling
chain that has been implicated in Ras activation, it has been
perplexing why cultured Nf12/2 cells are hypersensitive to
GM-CSF but not IL-3 in progenitor colony-forming as-
says. One explanation that has been suggested previously is
that p120 GAP, which is abundant and active in Nf12/2
hematopoietic cells (27, 30), is able to downregulate Ras-
GTP when it associates in a complex with the IL-3 recep-
tor and other proteins, but not when Ras associates with
the GM-CSF receptor (27, 30). Biochemical evidence that
MAP kinase is hyperactivated in c-kit1 Nf12/2 cells in re-
sponse to IL-3, or SCF (Fig. 5), and cell culture data show-
ing that SCF alone and in combination with IL-3 or GM-
CSF induce a hypersensitive pattern of in vitro growth in
Nf12/2 cells (Fig. 2), suggest that aberrant intracellular sig-
naling occurs in response to IL-3, GM-CSF, and SCF.
However, the biochemical abnormality is not translated to
hypersensitive colony formation in response to IL-3 only.
It is possible that SCF and GM-CSF activate downstream
signaling molecules important for terminal differentiation
that are not induced by IL-3. For example, focal adhesion
kinase is a recently identified kinase involved in the termi-
nal differentiation of myeloid cells that is activated in re-
sponse to GM-CSF (58) and SCF (59) but not IL-3. Nf1-
deficient hematopoietic cells and cell lines should prove
useful for further characterizing signaling pathways that are
differentially activated and regulated in response to GM-
CSF and IL-3. Our studies of purified Sca11lin2/dim cells
suggest that the hypersensitive pattern of colony formation
is intrinsic to the progenitors and is not dependent on ac-
cessory cells as suggested by some (31–33), but not all (21),
previous studies in JCML cells.
Cultures established from primary d13.5 Nf12/2 fetal
liver cells also demonstrated an increase in the numbers of
primitive progenitor (HPP-CFC) cells in the fetal liver. In
fact the expansion in this compartment was greater than
was noted for more differentiated progenitors (LPP-CFC)
scored in simultaneous experiments (our unpublished re-
sults). As the HPP-CFC and LPP-CFC assays were per-
formed in the presence of saturating concentrations of he-
matopoietic growth factors, our data indicate that inactivation
of Nf1 is not only associated with a leftward shift in the
dose–response curves for colony formation in response to
exogenous growth factors but also with an absolute in-
crease in the numbers of clonogenic progenitors in vivo.
Preliminary data indicate that this increase in progenitors is
associated with a relative resistance of Nf12/2 cells to apop-
tosis upon withdrawal of hematopoietic growth factors
(Zhang, Y.-Y., and D.W. Clapp, unpublished results).
Biochemical data from c-kit positive hematopoietic cells
demonstrating constitutive activation of MAP kinase sig-
naling and a prolonged hyperactivation of MAP kinase ac-
tivity in response to stimulation with cytokines suggests
that deregulation of the Ras/MAP kinase pathway ac-
counts for the perturbations of in vitro colony growth. In-
deed, reducing the MAP kinase activity with an inhibitor
of MEK was associated with a profound, specific reduction
in colony formation from Nf12/2 c-kit1 cells. The elevated
and sustained levels of MAP kinase that we measured in re-
sponse to SCF, IL-3, or GM-CSF in highly progenitor-
enriched primary cells are consistent with the previous ob-
servation of a sustained elevation of Ras-GTP levels after
GM-CSF stimulation in Myb immortalized Nf12/2 fetal he-
matopoietic cell lines (27). Similarly, primary bone marrow
cells from children with NF1 and leukemia showed an ele-
vated percentage of Ras-GTP (30). Although the bio-
chemical data presented here, the predilection to myeloid
leukemia seen in children with NF1 and in Nf11/2 mice,
and the myeloid disorder that invariably develops in the re-
cipients of Nf12/2 fetal liver cells provide compelling evi-
dence that neurofibromin is essential to regulate Ras out-
put in myeloid lineage cells, future studies are indicated to
further delineate how neurofibromin modulates Ras in re-
sponse to cytokines such as SCF. In particular, p120 GAP
accounts for most of the in vivo and in vitro GTPase acti-
vating protein activity in bone marrow cells (30, 60, 61). It
is possible that p120 GAP is sequestered away from growth
factor receptor–Ras complexes in activated myeloid cells or
is inactivated by a more direct mechanism. In this respect,
the recent cloning of the gene encoding p62Dok (Dok) is of
interest as this protein is phosphorylated in leukemic cells
that carry the BCR-ABL translocation and phosphorylated1900 Nf1 Regulates Hematopoietic Progenitor Cell Growth
Dok selectively associates with p120 GAP through Src ho-
mology 2 (SH2) domains. Dok is rapidly phosphorylated in
hematopoietic cells in response to SCF (62). If the binding
of phosphorylated p62Dok inhibits the function of p120
GAP, cells that have been stimulated with SCF may require
neurofibromin to properly regulate Ras-GTP (neurofibro-
min does not contain SH2 domains [for review see references
4, 63, 64], and is unlikely to interact with Dok). Additional
biochemical data are required to examine if SCF-induced
phosphorylation of p62Dok affects the function of p120
GAP in normal and Nf1-deficient myeloid lineage cells.
In summary, we have shown that the loss of Nf1 results
in constitutive activation of Ras signaling in primitive and
lineage-restricted hematopoietic progenitors. This is associ-
ated with hyperresponsiveness to multiple growth factors in
biochemical and progenitor colony-forming assays, as well
as in expansion of myeloid compartments in Nf12/2embryos
and in adult recipients reconstituted with Nf12/2 fetal liver
cells. Taken together, these data strongly suggest that the
size and growth factor sensitivity of cells within these mul-
tiple hematopoietic compartments are regulated by neu-
rofibromin through its ability to effect the activation state
of the Ras/MAP kinase cascade. These data have implica-
tions for the use of GM-CSF antagonists to treat JCML.
On the one hand, our data showing that inactivation of
Nf1 results in aberrant signaling in response to other
growth factors provide evidence that GM-CSF–specific in-
hibitors might not show efficacy. However, mice that
overexpress GM-CSF develop a JCML-like disorder (65),
and in one recent study xenograft mice transplanted with
JCML cells and treated with antagonists to GM-CSF had a
significant reduction in JCML cells as compared with con-
trol mice treated with an isoimmune nonspecific antibody
(66). Thus, it may be that the loss of Nf1 results in aberrant
Ras activation in multiple myeloid compartments, the im-
portance of GM-CSF on terminal differentiation may be
pivotal to acquisition of the clinical disease, and it remains
possible that the clinical disorder will be abrogated by
blocking the GM-CSF receptor. Nf1 mice provide a valu-
able model system to test basic aspects of myeloid growth
control and to evaluate novel therapeutics directed against
hyperactive Ras.
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